QHP Capital-Backed Entities, Bend Bioscience, CoreRx, and Societal, Announce the Appointment of a New CEO

QHP Capital is delighted to announce the appointment of Owen Murray as the new CEO of the combined Bend Bioscience, CoreRx, and Societal entities (the “Company”). Mr. Murray joins us from Aprecia Pharmaceutical, where he served as CEO. With over 25 years of experience in the pharmaceutical and healthcare industries, he brings extensive expertise spanning early product development through commercialization.

Prior to his role at Aprecia, Mr. Murray held various senior positions at Cardinal Health, Lundbeck, Ovation Pharmaceuticals, and Recordati Rare Diseases. His experience in both the EU and US markets has equipped him with a profound understanding of global markets and regulatory dynamics.

“Mr. Murray’s deep knowledge of pharmaceutical commercialization, gained through his roles in both innovator and service businesses, will enable us to better address our partners’ needs and seize on exciting growth opportunities. His leadership will help us deliver solutions to the unmet needs of patients around the world,” stated Robin Smith Hoke, Chairman of the Board.

Mr. Murray holds a B.Sc. in Biochemistry with honors from the University of Wales, Swansea, an MBA with a management concentration from Seton Hall University, and an MS in Healthcare Leadership from Brown University.

Expressing his enthusiasm for his new role, Mr. Murray shared: “I am thrilled to join the Company and both lead and unite our established Bend, CoreRx, and Societal businesses. Our goal is to offer exceptional service to the global pharmaceutical industry. The integration of Bend Bioscience’s premier drug product design capabilities with CoreRx’s formulation development, clinical supply, and analytical services, alongside Societal’s robust commercial manufacturing and packaging, creates a powerful combination. The Company’s ability to design, scale, and manufacture complex drug products will provide a de-risked solution for our partners and their patients. As the global market increasingly focuses on supply reliability, I am confident that we will become the partner of choice for companies delivering innovative drug products to patients.”

About the Company

Together, Bend Bioscience, CoreRx, and Societal form an industry leading CDMO that provides innovative drug formulation, development, GMP manufacturing, and packaging and logistics services to pharmaceutical and biotech partners globally. The Company operates from three sites: its state-of-the-art campuses in Clearwater, FL and Gainesville, GA and its Bend Bioscience campus in Bend, OR. The Company delivers value-added solutions to its partners focused on oral solids, liquids, and topicals, including enhanced formulations utilizing particle engineering-based drug delivery technologies and spray dry dispersion. Learn more at www.bendbioscience.com, www.corerxpharma.com, and www.societalcdmo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806323592/en/